Why do so many people lack access to healthcare?

Millions of people living with diabetes?and rare blood disorders?cannot?get the life-saving?medicine?they need.?In some?instances, medicine?is too costly, or?travelling to see the doctor or to pick up a prescription requires a long journey and a loss of wages.?

In extreme situations, there is no doctor?to see, healthcare?clinic?to go to, or medicine on?the?shelf at the pharmacy.?

The stark reality is that only a fraction of patients?are?being treated today – and we need to close that gap so that?people?have affordable access to the medicines we manufacture and the care they need.?

The?barriers?are?complex?and?differ?from country to country,?but we?know from experience that change is possible.

Our ambition is to provide access to?the medicines we have available, to the greatest number of?people?living with?diabetes,?rare blood?diseases?and?rare endocrine disorders, while addressing varying levels of affordability.?

While limited public health data exists on children with type 1 diabetes, the unbearable truth is that only few live long enough to make it into the registries in many of the world’s poorest countries.

In 222 clinics across 14 low- and middle-income countries, our Changing Diabetes? in Children programme ensures care and life-saving insulin for children with type 1 diabetes. Today, the programme is providing medical care, insulin and supplies to more than 28,000 children. Our next ambition is to expand the programme to reach 100,000 by 2030.

In the video above, meet a type 1 super star,?Bilguissa?from Guinea.?Bilguissa?is part of a new generation of children and young adults living with type 1 diabetes in Guinea. With the support of doctors and nurses at the Changing Diabetes? in Children clinic, today she is a reflective community leader full of hope, capable of managing her own diabetes well, and of guiding and inspiring her younger peers.

Learn more about Changing Diabetes? in Children.

In?low- and middle-income countries,?we?put extra?focus?on?the most vulnerable?people living with diabetes. In more than two-thirds?of the countries where we operate, we have established affordability and access programmes?to help patients in need.?

These programmes are working to answer tough questions, like:

  • How do we encourage more patients to enrol in affordability programmes?

  • How?do we design?insulins that don’t require cooling and can therefore travel further?

  • How can we simplify?medicine?supply chains to drive down price?

We are working on these questions?with a strong?commitment?to?making insulin available to all.?Read on and?learn more about our commitment to affordable?treatment and access to?diabetes?care.?

Mithila Hag Farin and her mother. Mithila lives in Bangladesh and has type 1 diabetes.

We have made a?commitment to continue to have?a low-cost insulin in our product portfolio and?produce and make?human insulin available for years to come. This is?our Access to Insulin Commitment.?

With?our new?Defeat Diabetes?strategy,?we are?lowering?the ceiling price for low- and middle-income countries, and at the same time working to expand affordability programmes in the US and elsewhere in the world.

In 2001, we launched a ground breaking policy to lower the cost of human insulin in the most resource-constrained. Today, our policy covers a total of 76 countries, home to a third of the world’s diabetes population, as well as selected humanitarian organisations.

Our commitment builds on the following principles:

  • We will continue to be the leading supplier of low-priced human insulin in the world.
  • We will guarantee to provide low-priced human insulin in the poorest parts of the world for many years to come, including Least Developed Countries (LDCs) as defined by the UN, other low-income countries as defined by the World Bank and middle-income countries where large low-income populations lack sufficient health coverage, as well as selected humanitarian organisations where the commitment is global.
  • We will guarantee a ceiling price of human insulin at USD 3 per vial.
  • We will address challenges in insulin distribution and healthcare capacity that often prevent low-cost insulin from reaching the most vulnerable people.

We recognise that?it is not only low- and middle-income countries?where affording healthcare is a challenge.

In the United States,?some people living with diabetes?are increasingly finding it hard to pay for their healthcare, including our diabetes medicines.

Ensuring access and affordability is a responsibility we share with all involved in healthcare and we are going to do our part.

See our efforts to make medicine affordable for US patients.

Part of Novo Nordisk’s contribution to promoting access to care?is our continued long-term financial commitment to?the??World?Diabetes Foundation.?

The World Diabetes Foundation was established by Novo Nordisk in 2002 as an independent trust dedicated to the prevention and treatment of diabetes in developing countries. The Foundation supports sustainable partnerships and acts as a catalyst to help others do more.

Our?current commitment?to the Foundation is?DKK 1.69 billion (USD 277 million)?covering the period up to?2024.

Watch the video above to learn more about the?life-saving work?driven by the?World Diabetes Foundation.

In?some?countries,?people living with?haemophilia?may be in a situation where they are not authorised to store their haemophilia medication at home. For example, during the?COVID-19 crisis,?they?have not been able to?visit hospitals to seek treatment.?

When people living with a rare blood disease face these situations, we work with local health authorities and partner organisations to provide financial support?for medicine and treatment?home delivery.?

To ensure clear and transparent relationships, our initiatives are designed in dialogue with policy makers,?for?support services?related to patient?training, delivery and?medicine?storage.

The Novo Nordisk Haemophilia Foundation is a grant-making, non-profit organisation that strives to improve access to care for people with haemophilia and rare bleeding disorders in developing and emerging countries.

Haemophilia is a hereditary bleeding disorder affecting one in 10,000 people.?With three out of four people with haemophilia living in the developing world,?there is urgent need to ensure they have access to ?diagnosis?and?adequate care.

You can also?learn more about the?Novo Nordisk Haemophilia Foundation?by visiting their website, where you will find out how the foundation is ‘Impacting care. Together’.?

Immy Anne Anyango and her sister live in Uganda. Immy has type 1 diabetes and is enrolled in the Changing Diabetes?? in Children programme.

Americans?using our $25 low-cost insulin programme.

people with diabetes?treated with our human insulin at a maximum of?USD 3 per 10ml vial.

people?using our?diabetes care products globally.

people with haemophilia and family members benefitting?from educational activities?led by the?Novo Nordisk Haemophilia Foundation.